Metrics to compare | NCEL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNCELPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.3x | −2.3x | −0.3x | |
PEG Ratio | −0.21 | −0.04 | 0.00 | |
Price/Book | 2.6x | −0.6x | 2.6x | |
Price / LTM Sales | - | 4.9x | 3.0x | |
Upside (Analyst Target) | - | 211.5% | 54.6% | |
Fair Value Upside | Unlock | 13.3% | 8.6% | Unlock |
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.